Product image of Ledraxen (Enoxaparin Sodium) supplied by GNH India

Ledraxen

Active Ingredient:
Enoxaparin Sodium
Origin:
EU

Ledraxen (Enoxaparin Sodium)

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat deep vein thrombosis and pulmonary embolism, and to provide anticoagulation during haemodialysis procedures.

GNH India supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Venipharm

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ledraxen (enoxaparin sodium) is used in the venous thromboembolism pathway to prevent clot formation.

  • Deep vein thrombosis (DVT): prevents clot formation in the deep veins of the legs.
  • Pulmonary embolism (PE): reduces the risk of emboli traveling to the lungs.
  • Haemodialysis anticoagulation: maintains circuit patency during haemodialysis sessions.

How It Works

  • Enoxaparin sodium enhances the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin) by binding to antithrombin III. This accelerates the inactivation of clotting factors, thereby reducing thrombin generation and preventing fibrin clot formation in the vascular system. The selective inhibition of factor Xa provides a predictable anticoagulant response with a reduced need for routine laboratory monitoring.

Side Effects

Enoxaparin sodium may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Injection site bruising or pain.
  • Minor bleeding such as nosebleeds or gum bleeding.
  • Hematuria (blood in urine).
  • Gastrointestinal upset or nausea.
  • Elevated liver enzymes (transient).

Serious or Rare Side Effects

  • Major hemorrhage (internal or intracranial bleeding).
  • Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT).
  • Allergic reactions such as rash, urticaria, or anaphylaxis.
  • Spinal or epidural hematoma (with neuraxial procedures).

Precautions & Warnings

When using Ledraxen, clinicians should consider several safety measures to minimize risk.

  • Renal impairment: adjust dose or monitor anti‑Xa levels.
  • Concomitant anticoagulants: avoid combined use unless medically justified.
  • Recent surgery or trauma: assess bleeding risk before administration.
  • Pregnancy and lactation: use only if benefit outweighs potential risk.
  • History of heparin‑induced thrombocytopenia: contraindicated.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Avoid Interactions

Enoxaparin sodium can interact with other medicines, affecting its anticoagulant effect.

Major Interactions (Avoid)

  • Concurrent use with other anticoagulants (warfarin, direct oral anticoagulants) – high bleeding risk.
  • Antiplatelet agents (aspirin, clopidogrel) – increased hemorrhage.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) – potentiates bleeding.

Moderate Interactions (Monitor Closely)

  • Thrombolytic agents (tPA) – enhanced anticoagulation.
  • Selective serotonin reuptake inhibitors (SSRIs) – may increase bleeding tendency.
  • ACE inhibitors or ARBs – monitor for additive hypotensive effects.

Frequently Asked Questions

Ledraxen, containing enoxaparin sodium, is indicated for the prevention and treatment of deep vein thrombosis, the prevention of pulmonary embolism, and for anticoagulation during haemodialysis procedures.

Enoxaparin sodium binds to antithrombin III, markedly enhancing its inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This reduces thrombin generation and blocks the formation of fibrin clots, providing anticoagulation.

The dose of Ledraxen is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical situation. No fixed regimen is provided here.

Safety data for enoxaparin in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and under close medical supervision.

To order Ledraxen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Compared with unfractionated heparin, enoxaparin offers more predictable pharmacokinetics, a longer half‑life, and requires less routine monitoring. Compared with direct oral anticoagulants, it is administered parenterally and is often preferred in settings such as haemodialysis or when rapid reversal is needed.

Ledraxen should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, light, and extreme temperature fluctuations to maintain stability.

Ledraxen is administered by subcutaneous injection, intravenous injection, or added to the haemodialysis circuit, depending on the clinical indication. Administration technique follows standard aseptic practices and the prescribing clinician’s instructions.

The most serious risks include major bleeding events such as intracranial hemorrhage, severe gastrointestinal bleeding, and heparin‑induced thrombocytopenia (HIT). Prompt recognition and medical intervention are essential if these occur.

Ledraxen is contraindicated in patients with a known hypersensitivity to enoxaparin or other low molecular weight heparins, and in those with a history of heparin‑induced thrombocytopenia. Caution is also advised for patients with active major bleeding or severe uncontrolled hypertension.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Enoxaparin Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT